BNT112
Showing 1 - 8 of 8
COVID-19 Trial in Canada (mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant])
Recruiting
- COVID-19
- mRNA-1273 SARS-CoV-2 vaccine
- +4 more
-
Edmonton, Alberta, Canada
- +7 more
Mar 7, 2022
SARS-CoV-2 Infection, COVID-19 Trial in Australia, New Zealand (BNT162b2, Placebo, Seasonal Inactivated Influenza Vaccine)
Completed
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
- +2 more
-
Brookvale, New South Wales, Australia
- +25 more
Nov 22, 2023
Coronavirus Trial in Oxford (ChAdOx1 nCov-19)
Completed
- Coronavirus
- ChAdOx1 nCov-19
-
Oxford, United KingdomCCVTM, University of Oxford, Churchill Hospital
Oct 21, 2022
Children Aged 5-11 Years Following Vaccination Against COVID-19
Recruiting
- COVID-19 Vaccine
-
Petach Tikva, IsraelSchneider Children's Medical Center
Jan 24, 2022
Acquired Brain Injury, Mild Cognitive Impairment, Mild Neurocognitive Disorder Trial in Boston (Cognitive Computerized Training)
Recruiting
- Acquired Brain Injury
- +2 more
- Cognitive Computerized Training
-
Boston, MassachusettsBrigham and Women's Hospital
Nov 8, 2023
OCD, Quality of Life Trial in Porto Alegre (Radiosurgery)
Unknown status
- OCD
- Quality of Life
- Radiosurgery
-
Porto Alegre, Rio Grande Do Sul, BrazilHospital de Clínicas de Porto Alegre
Feb 9, 2021
Aphasia, Cerebrovascular Stroke Trial in Boston, Philadelphia (Transcranial Magnetic Stimulation, Repetitive)
Completed
- Aphasia
- Cerebrovascular Stroke
- Transcranial Magnetic Stimulation, Repetitive
-
Boston, Massachusetts
- +2 more
Dec 1, 2016